Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clovis Oncology Inc CLVSQ

Healthcare Biotechnology
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications... see more

Recent & Breaking News (PINL:CLVSQ)

The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Benzinga.com  October 31, 2018

Clovis Oncology Announces Third Quarter 2018 Operating Results

Business Wire October 30, 2018

The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio

Benzinga.com  October 30, 2018

The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering

Benzinga.com  October 24, 2018

The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

Benzinga.com  October 23, 2018

45 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  October 22, 2018

Clovis Oncology présente les résultats initiaux du programme TRITON en cours sur le Rubraca® (rucaparib) contre le cancer de la prostate résistant à la castration métastatique (CPRCm) au congrès 2018 de l'ESMO

Business Wire October 22, 2018

58 Biggest Movers From Friday

Benzinga.com  October 22, 2018

The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Benzinga.com  October 21, 2018

Clovis Oncology Presents Initial Results from the Ongoing Rubraca® (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer (mCRPC) at ESMO 2018 Congress

Business Wire October 19, 2018

Analysis: Positioning to Benefit within Clovis Oncology, Destination Maternity, MSG Networks, Lindblad Expeditions, NetScout, and ANI Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire October 18, 2018

Clovis Oncology to Announce Third Quarter 2018 Financial Results and Host Webcast Conference Call on October 30

Business Wire October 16, 2018

The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Benzinga.com  October 12, 2018

Clovis Oncology Appoints Two New Directors to its Board

Business Wire October 11, 2018

The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares

Benzinga.com  October 11, 2018

Clovis Oncology to Highlight Results from Rubraca® (rucaparib) TRITON Prostate Program at ESMO 2018 Congress

Business Wire October 3, 2018

45 Biggest Movers From Yesterday

Benzinga.com  October 3, 2018

Mid-Afternoon Market Update: Stitch Fix Falls After Q4 Results; Pyxus International Shares Climb

Benzinga.com  October 2, 2018

38 Stocks Moving In Tuesday's Mid-Day Session

Benzinga.com  October 2, 2018

Clovis Oncology Receives Breakthrough Therapy Designation for Rubraca® (rucaparib) for Treatment of BRCA1/2-Mutated Metastatic Castration Resistant Prostate Cancer (mCRPC)

Business Wire October 2, 2018